drugset
drugset / Trial / NCT04888949

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

NCT04888949 ↗

Phase 2 Completed 15 enrolled Rohto Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.

Timeline

Start
2021-06-15
Primary completion
2023-05-18
Completion
2023-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ADR-001 Cell therapy 1e+08 cells Intravenous

Indications

COVID-19